This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Blueprint Medicines (BPMC) Q4 Earnings Beat, Revenues In Line
by Zacks Equity Research
Blueprint Medicines' (BPMC) earnings beat estimates in the fourth quarter of 2020 while revenues meet the same. Shares up.
Is a Beat in Store for Moderna (MRNA) This Earnings Season?
by Zacks Equity Research
Investor focus is likely to be on any update on the timeline of filing for emergency use authorization of Modena's (MRNA) coronavirus vaccine candidate on the fourth-quarter earrings call.
What's in the Cards for Arcturus (ARCT) This Earnings Season?
by Zacks Equity Research
Arcturus (ARCT) is likely to discuss the progress of its COVID-19 vaccine candidate on the fourth-quarter earnings call.
Editas (EDIT) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Editas' (EDIT) fourth-quarter earnings call, investor focus will be on the company's progress with the development of its CRISPR-based experimental candidate, EDIT-101.
What's in the Cards for Sarepta (SRPT) This Earnings Season?
by Zacks Equity Research
Sarepta Therapeutics' (SRPT) fourth-quarter results are expected to reflect the ongoing COVID-19 impact. Launch plans for casimersen is what investors are expected be focused on.
Repligen (RGEN) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Repligen's (RGEN) fourth-quarter earnings call, investor focus will be on sales performance of its product franchisees - filtration, chromatography, protein and process analytics.
AzurRx (AZRX) Starts Dosing in Pancreatic Insufficiency Study
by Zacks Equity Research
AzurRX (AZRX) is developing its pipeline candidate, MS1819, as monotherapy as well in combination with standard of care for treating exocrine pancreatic insufficiency in patients with cystic fibrosis.
Biotech Stock Roundup: ALXN Pauses Study, ACRS & GRTS Surge, & Other Updates
by Zacks Equity Research
The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Alexion (ALXN), Aclaris (ACRS) and Biohaven (BHVN).
Lexicon (LXRX) Soars on FDA Permission for Sotagliflozin NDA
by Zacks Equity Research
Lexicon (LXRX) announces that data from two late-stage studies on its type II diabetes candidate, sotagliflozin, can support a regulatory approval application.
Lexicon (LXRX) Starts Dosing in Post-Herpetic Neuralgia Study
by Zacks Equity Research
Lexicon (LXRX) initiates dosing in a mid-stage study on LX9211 for the treatment of post-herpetic neuralgia.
Moving Average Crossover Alert: Lexicon Pharmaceuticals (LXRX)
by Zacks Equity Research
Lexicon Pharmaceuticals (LXRX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Is the Options Market Predicting a Spike in Lexicon Pharmaceuticals (LXRX) Stock?
by Zacks Equity Research
Investors need to pay close attention to Lexicon Pharmaceuticals (LXRX) stock based on the movements in the options market lately.
Lexicon Pharmaceuticals (LXRX) Q3 Earnings Beat Estimates
by Zacks Equity Research
Lexicon (LXRX) delivered earnings and revenue surprises of 57.78% and -94.43%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Lexicon (LXRX) delivered earnings and revenue surprises of -12.28% and 5.38%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Lexicon Pharmaceuticals (LXRX) Q2 Earnings Expected to Decline
by Zacks Equity Research
Lexicon (LXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Lexicon (LXRX) delivered earnings and revenue surprises of 4.55% and 11.47%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Lexicon (LXRX) delivered earnings and revenue surprises of 36.84% and -17.62%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Lexicon Pharmaceuticals (LXRX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Lexicon (LXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Lexicon (LXRX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Lexicon (LXRX) stock based on the movements in the options market lately.
Are Investors Undervaluing Lexicon Pharmaceuticals (LXRX) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Top Ranked Value Stocks to Buy for November 13th
by Zacks Equity Research
Here are three stocks with buy rank and strong value characteristics for investors to consider today, November 13th
Lexicon Pharmaceuticals (LXRX) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Lexicon (LXRX) delivered earnings and revenue surprises of 48.85% and 2146.84%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Lexicon Pharmaceuticals (LXRX) to Report Q3 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Lexicon (LXRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Small Caps Win in September: 5 Best ETFs & Stocks
by Sweta Killa
We highlight five small-cap ETFs and stocks that have outperformed in September. These could be excellent plays for investors should the same trends prevail.
Are Options Traders Betting on a Big Move in Lexicon Pharmaceuticals (LXRX) Stock?
by Zacks Equity Research
Investors need to pay close attention to Lexicon Pharmaceuticals (LXRX) stock based on the movements in the options market lately.